Obesity Surgery

, Volume 28, Issue 10, pp 3246–3252 | Cite as

The Impacts of Gastroileostomy Rat Model on Glucagon-like Peptide-1: a Promising Model to Control Type 2 Diabetes Mellitus

  • Behrouz Keleidari
  • Rastin Mohammadi Mofrad
  • Shahab Shahabi ShahmiriEmail author
  • Mohammad Hossein Sanei
  • Mohsen Kolahdouzan
  • Erfan Sheikhbahaei
Original Contributions



One of the new current treatment options for Diabetes Mellitus is about increasing glucagon-like peptide-1 (GLP-1) activity. GLP-1 with its incretin effect showed major role in glucose homeostasis. Gastroileostomy can increase GLP-1 secretion by rapid delivery of undigested food to the terminal ileum. We studied the early effects of a gastroileostomy on serum levels of GLP-1, glucose, and insulin in rats.


Gastroileostomies with side-to-side anastomosis were performed on 15 male New Zealand rats. Blood samples were obtained before and 1 week after the gastroileostomy.


Our results showed that the rats lost a lot of weight from start (330 ± 15 g) to the end (240 ± 25 g) of the experiment (p = 0.048). The data analysis showed that the gastroileostomy surgery elevates the level of GLP-1in plasma significantly (89.1852 vs. 177.440 respectively; p < 0.001) and caused a significant decrease in plasma glucose as well (92.00 and 66.29 mg/dL respectively; p < 0.001). However, the insulin state elevated after the surgery significantly (8.03 vs. 9.89; p < 0.001).


In this study, we showed the effectiveness of gastroileostomy treatment to decrease body weight and plasma glucose with increased GLP-1 in rats. This small rat model suggests the potential of this surgery to treat type 2 diabetes mellitus.


Glucagon-like peptide Gastroileostomy Diabetes mellitus Incretin Glucose 



The authors acknowledge Mr. Amirsalar Moazen Safaei and Mr. Aria Azarshahi for their help in proofreading this manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding Resource

No fund received for this research.

Ethics Statements

This research commenced after fulfilling all of the ethical statements and receiving its approval from department of ethics in medical research. All procedures were conducted in agreement with the National Institutes of Health Guide for Care and Use of Laboratory Animals.


  1. 1.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.Google Scholar
  2. 2.
    Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab. 2004;89(7):3469–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;10:CD006423.Google Scholar
  4. 4.
    Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63(1):9–19.CrossRefPubMedGoogle Scholar
  5. 5.
    Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011;2(2):101–21.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Stoffers DA, Desai BM, DeLeon DD, et al. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes. 2003;52(3):734–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Parkes DJC, Smith P, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res. 2001;53:260–7.CrossRefGoogle Scholar
  11. 11.
    Stearns AT, Balakrishnan A, Tavakkolizadeh A. Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport. Am J Physiol Gastrointest Liver Physiol. 2009;297(5):G950–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Johannessen H, Kodama Y, Zhao CM, et al. Eating behavior and glucagon-like peptide-1-producing cells in interposed ileum and pancreatic islets in rats subjected to ileal interposition associated with sleeve gastrectomy. Obes Surg. 2013;23(1):39–49.CrossRefPubMedGoogle Scholar
  13. 13.
    De Robertis E, Zito Marinosci G, Romano GM, et al. The use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impact. Clinicoecon Outcomes Res. 2016;8:317–22.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Murphy R, Evennett NJ, Clarke MG, et al. Sleeve gastrectomy versus Roux-en-Y gastric bypass for type 2 diabetes and morbid obesity: double-blind randomised clinical trial protocol. BMJ Open. 2016;6(7):e011416.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Keidar A, Hershkop KJ, Marko L, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: a randomised trial. Diabetologia. 2013;56(9):1914–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Mahdy T, Schou C. Efficacy of single anastomosis sleeve ileal (SASI) bypass for type-2 diabetic morbid obese patients: gastric bipartition, a novel metabolic surgery procedure: a retrospective cohort study. Int J Surg. 2016;34:28–34.CrossRefPubMedGoogle Scholar
  17. 17.
    Salama TMS, Sabry K, El Ghamrini Y. Single anastomosis sleeve ileal bypass: new step in the evolution of bariatric surgeries. J Investig Surg. 2017;30(5):291–6.CrossRefGoogle Scholar
  18. 18.
    Campos J, Ramos A, Szego T, et al. The role of metabolic surgery for patients with obesity grade I and clinically uncontrolled type 2 diabetes. Arq Bras Cir Dig. 2016;29:102–6.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Rizvi AA. The evolving role of bariatric surgery in patients with type 1 diabetes and obesity. Integr Obes Diabetes. 2016;2(2):195–9.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Vetter ML, Cardillo S, Rickels MR, et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009;150(2):94–103.CrossRefPubMedGoogle Scholar
  21. 21.
    Ashrafian H, le Roux CW. Metabolic surgery and gut hormones—a review of bariatric entero-humoral modulation. Physiol Behav. 2009;97(5):620–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Jurowich CF, Otto C, Rikkala PR, et al. Ileal interposition in rats with experimental type 2 like diabetes improves glycemic control independently of glucose absorption. J Diabetes Res. 2015;2015:490365.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nausheen S, Shah IH, Pezeshki A, et al. Effects of sleeve gastrectomy and ileal transposition, alone and in combination, on food intake, body weight, gut hormones, and glucose metabolism in rats. Am J Physiol Endocrinol Metab. 2013;305(4):E507–18.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhang H, Li J, Li Z, et al. Increased GLP-1 response after gavage-administration of glucose in UCP2-deficient mice. Horm Metab Res. 2012;44(2):86–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Phys. 1997;273(4 Pt 1):G920–7.Google Scholar
  26. 26.
    Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317(3):1106–13.CrossRefPubMedGoogle Scholar
  27. 27.
    Taqi E, Wallace LE, de Heuvel E, et al. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg. 2010;45(5):987–95.CrossRefPubMedGoogle Scholar
  28. 28.
    Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery. 2007;142(1):74–85.CrossRefPubMedGoogle Scholar
  29. 29.
    Li J, Lai D, Wu D. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy to treat morbid obesity-related comorbidities: a systematic review and meta-analysis. Obes Surg. 2016;26(2):429–42.CrossRefPubMedGoogle Scholar
  30. 30.
    Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Mahawar KK, Parikh C, Carr WR, et al. Primary banded Roux-en-Y gastric bypass: a systematic review. Obes Surg. 2014;24(10):1771–92.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Isfahan Minimally Invasive Surgery and Obesity (IMISO) Center, Department of SurgeryIsfahan University of Medical SciencesIsfahanIran
  2. 2.Department of SurgeryIsfahan University of Medical SciencesIsfahanIran
  3. 3.Department of Pathology, Al Zahra University HospitalIsfahan University of Medical SciencesIsfahanIran
  4. 4.Department of Thoracic Surgery, Al Zahra University HospitalIsfahan University of Medical SciencesIsfahanIran
  5. 5.Student Research Committee, Cardiovascular Research InstituteIsfahan University of Medical SciencesIsfahanIran

Personalised recommendations